Financhill
Sell
22

STXS Quote, Financials, Valuation and Earnings

Last price:
$1.95
Seasonality move :
-6.29%
Day range:
$1.78 - $1.86
52-week range:
$1.66 - $3.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.79x
P/B ratio:
25.68x
Volume:
305.8K
Avg. volume:
494.9K
1-year change:
-25.31%
Market cap:
$156.1M
Revenue:
$26.9M
EPS (TTM):
-$0.30

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
STXS
Stereotaxis
$6.4M -$0.07 -0.07% -20.83% $4.50
CUTRQ
Cutera
-- -- -- -- --
ELMD
Electromed
$15.3M -- 13.91% -- $37.00
IRIX
IRIDEX
$12.8M -$0.12 -2.72% -18.18% --
MYO
Myomo
$9.9M -$0.02 145.61% -20% $9.25
TMDX
TransMedics Group
$109.5M $0.15 27.41% -31.06% $102.86
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
STXS
Stereotaxis
$1.83 $4.50 $156.1M -- $0.00 0% 5.79x
CUTRQ
Cutera
$0.02 -- $438K -- $0.00 0% 0.00x
ELMD
Electromed
$24.62 $37.00 $210.7M 32.83x $0.00 0% 3.70x
IRIX
IRIDEX
$1.13 -- $18.8M -- $0.00 0% 0.38x
MYO
Myomo
$5.19 $9.25 $178.4M -- $0.00 0% 6.02x
TMDX
TransMedics Group
$68.51 $102.86 $2.3B 67.83x $0.00 0% 5.46x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
STXS
Stereotaxis
-- 1.401 -- 0.74x
CUTRQ
Cutera
-- -3.861 -- --
ELMD
Electromed
-- 1.614 -- 4.68x
IRIX
IRIDEX
51.25% 1.329 9.47% 0.73x
MYO
Myomo
-- 2.236 -- 2.82x
TMDX
TransMedics Group
69.02% 2.445 24.3% 7.25x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
STXS
Stereotaxis
$3.2M -$7.6M -139.2% -139.2% -120.3% -$4.3M
CUTRQ
Cutera
-- -- -- -- -- --
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
IRIX
IRIDEX
$4.3M -$1.9M -146.36% -157.91% -16.15% -$3.1M
MYO
Myomo
$8.6M -$245.3K -48.64% -48.64% -2.03% $2.5M
TMDX
TransMedics Group
$72M $8.6M 5.12% 19.17% 8.68% $6.1M

Stereotaxis vs. Competitors

  • Which has Higher Returns STXS or CUTRQ?

    Cutera has a net margin of -118.53% compared to Stereotaxis's net margin of --. Stereotaxis's return on equity of -139.2% beat Cutera's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    CUTRQ
    Cutera
    -- -- --
  • What do Analysts Say About STXS or CUTRQ?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 145.9%. On the other hand Cutera has an analysts' consensus of -- which suggests that it could grow by 9116.59%. Given that Cutera has higher upside potential than Stereotaxis, analysts believe Cutera is more attractive than Stereotaxis.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    CUTRQ
    Cutera
    0 0 0
  • Is STXS or CUTRQ More Risky?

    Stereotaxis has a beta of 1.546, which suggesting that the stock is 54.601% more volatile than S&P 500. In comparison Cutera has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.755%.

  • Which is a Better Dividend Stock STXS or CUTRQ?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cutera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Cutera pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or CUTRQ?

    Stereotaxis quarterly revenues are $6.3M, which are larger than Cutera quarterly revenues of --. Stereotaxis's net income of -$7.5M is higher than Cutera's net income of --. Notably, Stereotaxis's price-to-earnings ratio is -- while Cutera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.79x versus 0.00x for Cutera. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.79x -- $6.3M -$7.5M
    CUTRQ
    Cutera
    0.00x -- -- --
  • Which has Higher Returns STXS or ELMD?

    Electromed has a net margin of -118.53% compared to Stereotaxis's net margin of 12.11%. Stereotaxis's return on equity of -139.2% beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About STXS or ELMD?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 145.9%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.28%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    ELMD
    Electromed
    2 0 0
  • Is STXS or ELMD More Risky?

    Stereotaxis has a beta of 1.546, which suggesting that the stock is 54.601% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

  • Which is a Better Dividend Stock STXS or ELMD?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or ELMD?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than Electromed quarterly revenues of $16.3M. Stereotaxis's net income of -$7.5M is lower than Electromed's net income of $2M. Notably, Stereotaxis's price-to-earnings ratio is -- while Electromed's PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.79x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.79x -- $6.3M -$7.5M
    ELMD
    Electromed
    3.70x 32.83x $16.3M $2M
  • Which has Higher Returns STXS or IRIX?

    IRIDEX has a net margin of -118.53% compared to Stereotaxis's net margin of -16.69%. Stereotaxis's return on equity of -139.2% beat IRIDEX's return on equity of -157.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    IRIX
    IRIDEX
    37.33% -$0.12 $5.4M
  • What do Analysts Say About STXS or IRIX?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 145.9%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 76.99%. Given that Stereotaxis has higher upside potential than IRIDEX, analysts believe Stereotaxis is more attractive than IRIDEX.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    IRIX
    IRIDEX
    0 0 0
  • Is STXS or IRIX More Risky?

    Stereotaxis has a beta of 1.546, which suggesting that the stock is 54.601% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.936, suggesting its less volatile than the S&P 500 by 6.383%.

  • Which is a Better Dividend Stock STXS or IRIX?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or IRIX?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than IRIDEX quarterly revenues of $11.6M. Stereotaxis's net income of -$7.5M is lower than IRIDEX's net income of -$1.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.79x versus 0.38x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.79x -- $6.3M -$7.5M
    IRIX
    IRIDEX
    0.38x -- $11.6M -$1.9M
  • Which has Higher Returns STXS or MYO?

    Myomo has a net margin of -118.53% compared to Stereotaxis's net margin of -2.16%. Stereotaxis's return on equity of -139.2% beat Myomo's return on equity of -48.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    MYO
    Myomo
    71.39% -$0.01 $24.7M
  • What do Analysts Say About STXS or MYO?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 145.9%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 70.52%. Given that Stereotaxis has higher upside potential than Myomo, analysts believe Stereotaxis is more attractive than Myomo.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    MYO
    Myomo
    3 0 0
  • Is STXS or MYO More Risky?

    Stereotaxis has a beta of 1.546, which suggesting that the stock is 54.601% more volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

  • Which is a Better Dividend Stock STXS or MYO?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or MYO?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than Myomo quarterly revenues of $12.1M. Stereotaxis's net income of -$7.5M is lower than Myomo's net income of -$260.1K. Notably, Stereotaxis's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.79x versus 6.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.79x -- $6.3M -$7.5M
    MYO
    Myomo
    6.02x -- $12.1M -$260.1K
  • Which has Higher Returns STXS or TMDX?

    TransMedics Group has a net margin of -118.53% compared to Stereotaxis's net margin of 5.64%. Stereotaxis's return on equity of -139.2% beat TransMedics Group's return on equity of 19.17%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    TMDX
    TransMedics Group
    59.21% $0.19 $737.9M
  • What do Analysts Say About STXS or TMDX?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 145.9%. On the other hand TransMedics Group has an analysts' consensus of $102.86 which suggests that it could grow by 50.14%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    TMDX
    TransMedics Group
    5 3 0
  • Is STXS or TMDX More Risky?

    Stereotaxis has a beta of 1.546, which suggesting that the stock is 54.601% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.121, suggesting its more volatile than the S&P 500 by 112.09%.

  • Which is a Better Dividend Stock STXS or TMDX?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or TMDX?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than TransMedics Group quarterly revenues of $121.6M. Stereotaxis's net income of -$7.5M is lower than TransMedics Group's net income of $6.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 67.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.79x versus 5.46x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.79x -- $6.3M -$7.5M
    TMDX
    TransMedics Group
    5.46x 67.83x $121.6M $6.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock